Improvement in urinary retention due to recurrent anastomotic prostate cancer treated with various therapies by intra-arterial infusion of cisplatin and ifosfamide

Journal of Infection and Chemotherapy

Volumn 18, Issue 5, 2012, Pages 753-755

  Uemura, Keiichiro ^a   Nishihara, Kiyoaki ^a   Hayashi, Tokumasa ^a   Tomiyasu, Katsuro ^a   Matsuoka, Kei ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Hormone refractory prostate cancer; Intra arterial infusion chemotherapy; Urinary retention

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTRAMUSTINE PHOSPHATE; FLUTAMIDE; IFOSFAMIDE; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; ALOPECIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CASE REPORT; CASTRATION RESISTANT PROSTATE CANCER; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSURIA; FATIGUE; HUMAN; HUMAN TISSUE; LIVER INJURY; LOWER URINARY TRACT SYMPTOM; LYMPH NODE DISSECTION; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; RECTUM BIOPSY; RECURRENT CANCER; TRANSRECTAL ULTRASONOGRAPHY; TUMOR VOLUME; URINE RETENTION;

EID: 84871376251     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-011-0352-9     Document Type: Article

References (14)

1. Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, et al. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that has relapsed after initial maximum androgen blockade. J Urol. 2008;179:921-7.
2. Nishimura K, Nonomura N, Yasunaga Y, Takaha N, Inoue H, Sugao H, et al. Low dose of oral dexamethasone for hormonerefractory prostate carcinoma. Cancer. 2000;89:2570-6.
3. Tannock IF, De Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Eng J Med. 2004;351:1502-12.
4. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr., Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Eng J Med. 2004;351:1513-20.
5. Eisenberger M. Chemotherapy for endocrine resistant cancer for the prostate. Prog Clin Biol Res. 1990;359:155-64.
6. Scott WW, Gibbons RP, Johnson DE, Prout GR, Schmidt JD, Saroff J, et al. The continued evaluation of the effects of chemotherapy in patients with advanced carcinoma of the prostate. J Urol. 1976;116:211-3.
7. Murphy G, Priore R, Scardino P. Hormone-refractory metastatic prostate cancer treated with methotrexate, cyclophosphamide plus adriamycin, cis-platinum plus 5-fluorouracil plus cyclophosphamide. Urology. 1988;32:33-40.
8. DeWys WD, Begg CB, Brodovsky H, Greech R, Khandekar J. A comparative clinical trial of adriamycin and 5-fluorouracil in advanced prostatic cancer: prognostic factors and response. Prostate. 1983;4:1-11.
9. Maki Y, Tsushima T, Nasu Y, Kumon H, Ohmori H, Tanahashi T, et al. Combination chemotherapy with cis-platinum and ifosfamide for hormone unresponsive prostate cancer. Jpn J Urol. 1998;89:657-64.
10. Petrylak DP. Chemotherapy for the treatment of hormonerefractory prostate cancer. Eur Urol Supply. 2002;1:15-23.
11. Ueno K, Shinoda I, Takahashi Y, Kawamoto S, Yamamoto N, Kawada Y, et al. Intra-arterial chemotherapy for relapsed and hormone-resistant prostate cancer using reservoir system. Jpn Cancer Chemother. 1990;17:1783-7.
12. Sumiyoshi Y, Hashine K, Kasahara K, Akiyama M, Yokota K, Inoue Y, et al. Intermittent intra-arterial chemotherapy for the treatment of patients with bladder cancer or prostate cancer using implantable injection pump. Jpn J Urol. 1996;87:682-7.
13. Kuriyama M, Takeuchi T, Takahashi Y, Takeda A, Ishihara S, Ozeki S, et al. Intra-arterial chemotherapy using a reservoir for endocrine refractory prostate cancer. Cancer Chemother Pharmacol. 1994;35:27-30.
14. Oikawa H, Nakamura R, Nakasato T, Nishimura K, Sato H, Ehara S. Radiotherapy and concomitant intra-arterial docetaxel combined with systemic 5-fluorouracil and cisplatin for oropharyngeal cancer: a preliminary report-improvement of locoregional control of oropharyngeal cancer. Int J Radiat Oncol Biol Phys. 2009;75(2):338-42.